Sangamo presents IL23R-CAR-Tregs for treating Crohn's disease Oct. 26, 2021 Sangamo Therapeutics Inc. has reported preclinical results for IL23R-CAR-Tregs, a strategy based on chimeric antigen receptor (CAR)-modified regulatory T cells (Tregs) for the treatment of Crohn's disease.Read More